SCHEMBL4036294

SCHEMBL4036294

OC1CCN(c2ccc3nc(Nc4c(F)cccc4Cl)c4cncn4c3n2)CC1

nearest known ligand 0.58

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
LCK P06239 20/20 0.58
SRC P12931 1/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4045378 0.90 LCK (0.72) LCKSRC
SCHEMBL4038769 0.88 LCK (0.57) LCKSRC
SCHEMBL4036391 0.88 LCK (0.60) LCKSRC
SCHEMBL4036290 0.85 LCK (0.54) LCKSRC
SCHEMBL4040834 0.85 LCK (0.60) LCKSRC
SCHEMBL4039717 0.84 LCK (0.60) LCKSRC
SCHEMBL4037424 0.84 LCK (0.75) LCKSRC
SCHEMBL4039733 0.84 LCK (0.75) LCKSRC
SCHEMBL4038001 0.84 LCK (0.62) LCKSRC
SCHEMBL4038032 0.83 LCK (0.83) LCKSRC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1066286-B1 HETEROCYCLO-SUBSTITUTED IMIDAZOPYRAZINE PROTEIN TYROSINE KINASE INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2009-04-29 EP claimed
EP-1066286-A4 HETEROCYCLO-SUBSTITUTED IMIDAZOPYRAZINE PROTEIN TYROSINE KINASE INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2004-02-11 EP claimed
EP-1066286-A1 HETEROCYCLO-SUBSTITUTED IMIDAZOPYRAZINE PROTEIN TYROSINE KINASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2001-01-10 EP claimed
WO-1999045009-A1 HETEROCYCLO-SUBSTITUTED IMIDAZOPYRAZINE PROTEIN TYROSINE KINASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 1999-09-10 WO claimed
EP-1066286-B1 HETEROCYCLO-SUBSTITUTED IMIDAZOPYRAZINE PROTEIN TYROSINE KINASE INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2009-04-29 EP disclosed